Zafirlukast is a selctive leukotriene-receptor inhibitor of leukotriene D4 and E4, which are substances involved in inflammation. Cysteinyl leukotriene generation and receptor occupation are deemed to be related to asthma, including airway edema, smooth muscle narrowing, and modified cell activities relating to inflammation, which add to the signs and symptoms of asthma.